Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicine (MNM) products. AAA’s lead therapeutic product candidate, Lutathera®, is a novel MNM compound that AAA is currently developing for the treatment of neuroendocrine tumors, a significant unmet medical need. Founded in 2002, AAA has its headquarters in Saint-Genis-Pouilly, France. AAA currently has 22 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 530 employees in 13 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, The Netherlands, Belgium, Israel, U.S. and Canada). AAA reported sales of €109.3 million in 2016 (+23% vs. 2015). AAA is listed on the Nasdaq Global Select Market under the ticker “AAAP”. For more information, please visit: www.adacap.com.
AAA has a broad pipeline of products in development. In addition to the company lead product, Lutathera®, and its Gallium-68 Dotatate and Dotatoc products NetSpot and Somakit approved by the FDA and the EMA, Phase II studies have been initiated with Annexin V-128, a diagnostic 99mTc tracer for apoptosis and necrosis, and the company has other imaging and therapeutic radiopharmaceutical products in development.